Thyroid Isthmus Length and Iodine Turnover as Predictors of Successful Radioactive Iodine Therapy in Patients with Graves’ Disease
Table 1
Baseline clinical characteristics of patients with Graves’ disease.
Characteristic
Total patients ()
Age, years
44.1 ± 14.0
Sex (female, %)
67 (68.4%)
Follow-up duration, months
33.1 ± 14.0
BMI, kg/m2
23.4 ± 3.2
Isthmus, mm
5.4 ± 3.2
Thyroid volume, cm3
32.3 ± 21.0
Pre-RAI T3, ng/mL
1.85 ± 0.97
Pre-RAI free T4, ng/mL
2.05 ± 1.22
Undetectable TSH (n, %)
76 (77.6%)
Pre-RAI TRAb, IU/L
13.45 ± 14.21
Pre-RAI TSI, %
318.5 ± 208.7
RAI dose, mCi
11.7 ± 1.8
2-hour uptake, %
44.3 ± 22.5
24-hour uptake, %
66.0 ± 21.5
2-hour/24-hour ratio
0.65 ± 0.24
Serum selenium, μg/L
118.2 ± 17.1
Serum 25(OH)D, ng/dL
19.0 ± 9.1
Data are presented as mean ± SD or number (%). BMI: body mass index; RAI: radioactive iodine; TRAb: TSH receptor antibody; TSI: thyroid-stimulating immunoglobulin; 25(OH)D: 25-hydroxycholecalciferol.